Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

virbac sa - tramadolhydrochloride - oplossing voor injectie - tramadolhydrochloride 50 mg/ml, - tramadol - honden

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

intervet international - furosemide 50 mg/g - oplossing voor injectie - 50 mg/ml - furosemide 50 mg - furosemide - rund; hond; paard; kat

Europese Unie - Nederlands - EMA (European Medicines Agency)

orphelia pharma sas - clofarabine - precursorcel lymfoblastische leukemie-lymfoom - antineoplastische middelen - behandeling van acute lymfoblastische leukemie (all) bij pediatrische patiënten die een recidief hebben gehad of die refractair zijn na het ontvangen van ten minste twee eerdere regimes en waarbij er geen andere behandelingsoptie is die naar verwachting resulteert in een duurzame respons. de veiligheid en werkzaamheid zijn beoordeeld in studies van patiënten ≤ 21 jaar oud bij de eerste diagnose.

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

beaphar bv - fipronil; methopreen (s-vorm) - spot-on oplossing - fipronil 134 mg/ml; methopreen (s-vorm) 120,6 mg/ml, - fipronil, combinations - honden

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

beaphar bv - fipronil; methopreen (s-vorm) - spot-on oplossing - fipronil 268 mg/ml; methopreen (s-vorm) 241,2 mg/ml, - fipronil, combinations - honden

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

beaphar bv - fipronil; methopreen (s-vorm) - spot-on oplossing - fipronil 402 mg/ml; methopreen (s-vorm) 361,8 mg/ml, - fipronil, combinations - honden

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

beaphar bv - fipronil; methopreen (s-vorm) - spot-on oplossing - fipronil 50 mg/ml; methopreen (s-vorm) 60 mg/ml, - fipronil, combinations - fretten; katten

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

beaphar bv - fipronil; methopreen (s-vorm) - spot-on oplossing - fipronil 67 mg/ml; methopreen (s-vorm) 60,3 mg/ml, - fipronil, combinations - honden

Europese Unie - Nederlands - EMA (European Medicines Agency)

gilead sciences ireland uc - remdesivir - covid-19 virus infection - veklury is indicated for the treatment of coronavirus disease 2019 (covid 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

Europese Unie - Nederlands - EMA (European Medicines Agency)

samsung bioepis nl b.v. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastische middelen - aybintio in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. aybintio in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. zie rubriek 5 voor meer informatie over de status van humane epidermale groeifactorreceptor 2 (her2). 1 of the smpc. aybintio in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracyclinecontaining regimens in the adjuvant setting within the last 12 months should be excluded from treatment with aybintio in combination with capecitabine. raadpleeg sectie 5 voor meer informatie over her2-status. 1 of the smpc. aybintio, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. aybintio, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. 1 of the smpc). aybintio in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. aybintio, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. 1 of the smpc). aybintio, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. aybintio, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. 1 of the smpc). aybintio, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5. 1 of the smpc).